Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC22 plus ART in HIV-1 infection (Phase II, China)
CTR20220574Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Mar 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in human immunodeficiency virus infection (HIV), sponsored by Ascletis Pharma Inc.. Started Mar 2022; status: completed.
02
Drugs
envafolimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on CTR20220574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220574.